Hematologic malignancies in pregnancy: Management guidelines from an international consensus meeting

Michael Lishner, Irit Avivi, J. Apperley, Daan Dierickx, Andrew M. Evens, Monica Fumagalli, Irena Nulman, Fuat S. Oduncu, Fedro Alessandro Peccatori, Susan Robinson, Kristel Van Calsteren, Tineke Vandenbroucke, Frank Van Den Heuvel, F. Amant

Research output: Contribution to journalArticle

Abstract

Purpose: The incidence of hematologic malignancies during pregnancy is 0.02%. However, this figure is increasing, as women delay conception until a later age. Systemic symptoms attributed to the development of a hematologic cancermay overlapwith physiologic changes of pregnancy. A favorable prognosis is contingent upon early diagnosis and treatment. Therefore, a high index of suspicion is required by health care providers. Although timely, accurate diagnosis followed by appropriate staging is essential and should not be delayed due to pregnancy, management guidelines are lacking due to insufficient evidence-based research. Consequently, treatment is delayed, posing significant risks to maternal and fetal health, and potential pregnancy termination. This report provides guidelines for clinical management of hematologic cancers during the perinatal period, which were developed by a multidisciplinary team including an experienced hematologist/oncologist, a high-risk obstetrics specialist, a neonatologist, and experienced nurses, social workers, and psychologists. Methods: These guidelines were developed by experts in the field during the first International Consensus Meeting of PrenatalHematologicMalignancies, which took place in Leuven, Belgium, onMay 23, 2014. Results and Conclusion: This consensus summary equips health care professionals with novel diagnostic and treatment methodologies that aimfor optimal treatment of themother, while protecting fetal and pediatric health.

Original languageEnglish
Pages (from-to)501-508
Number of pages8
JournalJournal of Clinical Oncology
Volume34
Issue number5
DOIs
Publication statusPublished - Feb 10 2016

Fingerprint

Hematologic Neoplasms
Consensus
Guidelines
Pregnancy
Belgium
Therapeutics
Health Personnel
Obstetrics
Early Diagnosis
Nurses
Pediatrics
Psychology
Delivery of Health Care
Incidence
Health
Research
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hematologic malignancies in pregnancy : Management guidelines from an international consensus meeting. / Lishner, Michael; Avivi, Irit; Apperley, J.; Dierickx, Daan; Evens, Andrew M.; Fumagalli, Monica; Nulman, Irena; Oduncu, Fuat S.; Peccatori, Fedro Alessandro; Robinson, Susan; Van Calsteren, Kristel; Vandenbroucke, Tineke; Van Den Heuvel, Frank; Amant, F.

In: Journal of Clinical Oncology, Vol. 34, No. 5, 10.02.2016, p. 501-508.

Research output: Contribution to journalArticle

Lishner, M, Avivi, I, Apperley, J, Dierickx, D, Evens, AM, Fumagalli, M, Nulman, I, Oduncu, FS, Peccatori, FA, Robinson, S, Van Calsteren, K, Vandenbroucke, T, Van Den Heuvel, F & Amant, F 2016, 'Hematologic malignancies in pregnancy: Management guidelines from an international consensus meeting', Journal of Clinical Oncology, vol. 34, no. 5, pp. 501-508. https://doi.org/10.1200/JCO.2015.62.4445
Lishner, Michael ; Avivi, Irit ; Apperley, J. ; Dierickx, Daan ; Evens, Andrew M. ; Fumagalli, Monica ; Nulman, Irena ; Oduncu, Fuat S. ; Peccatori, Fedro Alessandro ; Robinson, Susan ; Van Calsteren, Kristel ; Vandenbroucke, Tineke ; Van Den Heuvel, Frank ; Amant, F. / Hematologic malignancies in pregnancy : Management guidelines from an international consensus meeting. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 5. pp. 501-508.
@article{a86fc79f96344180b1554bd41446ff8d,
title = "Hematologic malignancies in pregnancy: Management guidelines from an international consensus meeting",
abstract = "Purpose: The incidence of hematologic malignancies during pregnancy is 0.02{\%}. However, this figure is increasing, as women delay conception until a later age. Systemic symptoms attributed to the development of a hematologic cancermay overlapwith physiologic changes of pregnancy. A favorable prognosis is contingent upon early diagnosis and treatment. Therefore, a high index of suspicion is required by health care providers. Although timely, accurate diagnosis followed by appropriate staging is essential and should not be delayed due to pregnancy, management guidelines are lacking due to insufficient evidence-based research. Consequently, treatment is delayed, posing significant risks to maternal and fetal health, and potential pregnancy termination. This report provides guidelines for clinical management of hematologic cancers during the perinatal period, which were developed by a multidisciplinary team including an experienced hematologist/oncologist, a high-risk obstetrics specialist, a neonatologist, and experienced nurses, social workers, and psychologists. Methods: These guidelines were developed by experts in the field during the first International Consensus Meeting of PrenatalHematologicMalignancies, which took place in Leuven, Belgium, onMay 23, 2014. Results and Conclusion: This consensus summary equips health care professionals with novel diagnostic and treatment methodologies that aimfor optimal treatment of themother, while protecting fetal and pediatric health.",
author = "Michael Lishner and Irit Avivi and J. Apperley and Daan Dierickx and Evens, {Andrew M.} and Monica Fumagalli and Irena Nulman and Oduncu, {Fuat S.} and Peccatori, {Fedro Alessandro} and Susan Robinson and {Van Calsteren}, Kristel and Tineke Vandenbroucke and {Van Den Heuvel}, Frank and F. Amant",
year = "2016",
month = "2",
day = "10",
doi = "10.1200/JCO.2015.62.4445",
language = "English",
volume = "34",
pages = "501--508",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Hematologic malignancies in pregnancy

T2 - Management guidelines from an international consensus meeting

AU - Lishner, Michael

AU - Avivi, Irit

AU - Apperley, J.

AU - Dierickx, Daan

AU - Evens, Andrew M.

AU - Fumagalli, Monica

AU - Nulman, Irena

AU - Oduncu, Fuat S.

AU - Peccatori, Fedro Alessandro

AU - Robinson, Susan

AU - Van Calsteren, Kristel

AU - Vandenbroucke, Tineke

AU - Van Den Heuvel, Frank

AU - Amant, F.

PY - 2016/2/10

Y1 - 2016/2/10

N2 - Purpose: The incidence of hematologic malignancies during pregnancy is 0.02%. However, this figure is increasing, as women delay conception until a later age. Systemic symptoms attributed to the development of a hematologic cancermay overlapwith physiologic changes of pregnancy. A favorable prognosis is contingent upon early diagnosis and treatment. Therefore, a high index of suspicion is required by health care providers. Although timely, accurate diagnosis followed by appropriate staging is essential and should not be delayed due to pregnancy, management guidelines are lacking due to insufficient evidence-based research. Consequently, treatment is delayed, posing significant risks to maternal and fetal health, and potential pregnancy termination. This report provides guidelines for clinical management of hematologic cancers during the perinatal period, which were developed by a multidisciplinary team including an experienced hematologist/oncologist, a high-risk obstetrics specialist, a neonatologist, and experienced nurses, social workers, and psychologists. Methods: These guidelines were developed by experts in the field during the first International Consensus Meeting of PrenatalHematologicMalignancies, which took place in Leuven, Belgium, onMay 23, 2014. Results and Conclusion: This consensus summary equips health care professionals with novel diagnostic and treatment methodologies that aimfor optimal treatment of themother, while protecting fetal and pediatric health.

AB - Purpose: The incidence of hematologic malignancies during pregnancy is 0.02%. However, this figure is increasing, as women delay conception until a later age. Systemic symptoms attributed to the development of a hematologic cancermay overlapwith physiologic changes of pregnancy. A favorable prognosis is contingent upon early diagnosis and treatment. Therefore, a high index of suspicion is required by health care providers. Although timely, accurate diagnosis followed by appropriate staging is essential and should not be delayed due to pregnancy, management guidelines are lacking due to insufficient evidence-based research. Consequently, treatment is delayed, posing significant risks to maternal and fetal health, and potential pregnancy termination. This report provides guidelines for clinical management of hematologic cancers during the perinatal period, which were developed by a multidisciplinary team including an experienced hematologist/oncologist, a high-risk obstetrics specialist, a neonatologist, and experienced nurses, social workers, and psychologists. Methods: These guidelines were developed by experts in the field during the first International Consensus Meeting of PrenatalHematologicMalignancies, which took place in Leuven, Belgium, onMay 23, 2014. Results and Conclusion: This consensus summary equips health care professionals with novel diagnostic and treatment methodologies that aimfor optimal treatment of themother, while protecting fetal and pediatric health.

UR - http://www.scopus.com/inward/record.url?scp=84958744669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958744669&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.62.4445

DO - 10.1200/JCO.2015.62.4445

M3 - Article

VL - 34

SP - 501

EP - 508

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -